TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06082037: A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction

Sponsor: Sanofi · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 180 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$565,728

Rescue Site Savings

+$377,152

Unlock Full NCT06082037 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06082037 Rescue Dossier →